Kime KRT-D & Kime KRT-P

Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European heart journal. 2021;42(35):3427-3520. doi:10.1093/eurheartj/ehab364

Carson P, Anand I, O'Connor C, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. Journal of the American College of Cardiology. 2005;46(12):2329-2334. doi:10.1016/j.jacc.2005.09.016

Schrage B, Lund LH, Melin M, et al. Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2022;24(1):48-57. doi:10.1093/europace/euab233

Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ (Clinical research ed). 2007;335(7626):925. doi:10.1136/bmj.39343.511389.BE

Leyva F, Zegard A, Okafor O, et al. Survival after cardiac resynchronization therapy: results from 50 084 implantations. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2019;21(5):754-762. doi:10.1093/europace/euy267

Chatterjee NA, Roka A, Lubitz SA, et al. Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. European heart journal. 2015;36(41):2780-2789. doi:10.1093/eurheartj/ehv373

Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. European heart journal. 2006;27(16):1928-1932. doi:10.1093/eurheartj/ehl099

Gold MR, Daubert JC, Abraham WT, et al. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circulation Arrhythmia and electrophysiology. 2013;6(6):1163-1168. doi:10.1161/CIRCEP.113.000570

Marijon E, Leclercq C, Narayanan K, et al. Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study. European heart journal. 2015;36(41):2767-2776. doi:10.1093/eurheartj/ehv455

Al-Majed NS, McAlister FA, Bakal JA, et al. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Annals of internal medicine. 2011;154(6):401-412. doi:10.7326/0003-4819-154-6-201103150-00313

Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart (British Cardiac Society). 2015;101(22):1800-1806. doi:10.1136/heartjnl-2015-307634

Kutyifa V, Moss AJ, Solomon SD, et al. Reduced risk of life-threatening ventricular tachyarrhythmias with cardiac resynchronization therapy: relationship to left ventricular ejection fraction. European journal of heart failure. 2015;17(9):971-978. doi:10.1002/ejhf.311

Sapp JL, Parkash R, Wells GA, et al. Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial. Circulation Arrhythmia and electrophysiology. 2017;10(3). doi:10.1161/CIRCEP.116.004875

Gold MR, Linde C, Abraham WT, et al. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart rhythm. 2011;8(5):679-684. doi:10.1016/j.hrthm.2010.12.031

Barsheshet A, Wang PJ, Moss AJ, et al. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). Journal of the American College of Cardiology. 2011;57(24):2416-2423. doi:10.1016/j.jacc.2010.12.041

Leyva F, Zegard A, Umar F, et al. Long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2018;20(11):1804-1812. doi:10.1093/europace/eux357

Barra S, Boveda S, Providencia R, et al. Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate. Journal of the American College of Cardiology. 2017;69(13):1669-1678. doi:10.1016/j.jacc.2017.01.042

Kutyifa V, Geller L, Bogyi P, et al. Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience. European journal of heart failure. 2014;16(12):1323-1330. doi:10.1002/ejhf.185

Kober L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. The New England journal of medicine. 2016;375(13):1221-1230. doi:10.1056/NEJMoa1608029

Gras M, Bisson A, Bodin A, et al. Mortality and cardiac resynchronization therapy with or without defibrillation in primary prevention. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2020;22(8):1224-1233. doi:10.1093/europace/euaa096

Al-Sadawi M, Aslam F, Tao M, et al. Is CRT-D superior to CRT-P in patients with nonischemic cardiomyopathy? International Journal of Arrhythmia. 2023;24(1):3. doi:10.1186/s42444-023-00085-3

Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. The New England journal of medicine. 2009;361(14):1329-1338. doi:10.1056/NEJMoa0906431

Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. The New England journal of medicine. 2010;363(25):2385-2395. doi:10.1056/NEJMoa1009540

Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. Journal of the American College of Cardiology. 2008;52(23):1834-1843. doi:10.1016/j.jacc.2008.08.027

Hadwiger M, Dagres N, Haug J, et al. Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project. European heart journal. 2022;43(27):2591-2599. doi:10.1093/eurheartj/ehac053

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368

Normand C, Linde C, Bogale N, et al. Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?-findings from the ESC CRT Survey II. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2019;21(6):918-927. doi:10.1093/europace/euz002

Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. European heart journal. 2013;34(33):2592-2599. doi:10.1093/eurheartj/eht160

Barra S, Providencia R, Narayanan K, et al. Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. European heart journal. 2020;41(21):1976-1986. doi:10.1093/eurheartj/ehz773

Shen L, Jhund PS, Petrie MC, et al. Declining Risk of Sudden Death in Heart Failure. The New England journal of medicine. 2017;377(1):41-51. doi:10.1056/NEJMoa1609758

Medina-Ravell VA, Lankipalli RS, Yan GX, et al. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation. 2003;107(5):740-746. doi:10.1161/01.cir.0000048126.07819.37

Shukla G, Chaudhry GM, Orlov M, et al. Potential proarrhythmic effect of biventricular pacing: fact or myth? Heart rhythm. 2005;2(9):951-956. doi:10.1016/j.hrthm.2005.05.019

Leyva F, Zegard A, Acquaye E, et al. Outcomes of Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy. Journal of the American College of Cardiology. 2017;70(10):1216-1227. doi:10.1016/j.jacc.2017.07.712

Acosta J, Fernandez-Armenta J, Borras R, et al. Scar Characterization to Predict Life-Threatening Arrhythmic Events and Sudden Cardiac Death in Patients With Cardiac Resynchronization Therapy: The GAUDI-CRT Study. JACC Cardiovascular imaging. 2018;11(4):561-572. doi:10.1016/j.jcmg.2017.04.021

Linde C. CRT-P or CRT-D in heart failure patients: the RESET-CRT project-a prelude to the randomized controlled RESET-CRT study. European heart journal. 2022;43(27):2600-2602. doi:10.1093/eurheartj/ehac136

Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European heart journal. 2021;42(35):3427-3520. doi:10.1093/eurheartj/ehab364

Carson P, Anand I, O'Connor C, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. Journal of the American College of Cardiology. 2005;46(12):2329-2334. doi:10.1016/j.jacc.2005.09.016

Schrage B, Lund LH, Melin M, et al. Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2022;24(1):48-57. doi:10.1093/europace/euab233

Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ (Clinical research ed). 2007;335(7626):925. doi:10.1136/bmj.39343.511389.BE

Leyva F, Zegard A, Okafor O, et al. Survival after cardiac resynchronization therapy: results from 50 084 implantations. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2019;21(5):754-762. doi:10.1093/europace/euy267

Chatterjee NA, Roka A, Lubitz SA, et al. Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. European heart journal. 2015;36(41):2780-2789. doi:10.1093/eurheartj/ehv373

Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. European heart journal. 2006;27(16):1928-1932. doi:10.1093/eurheartj/ehl099

Gold MR, Daubert JC, Abraham WT, et al. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circulation Arrhythmia and electrophysiology. 2013;6(6):1163-1168. doi:10.1161/CIRCEP.113.000570

Marijon E, Leclercq C, Narayanan K, et al. Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study. European heart journal. 2015;36(41):2767-2776. doi:10.1093/eurheartj/ehv455

Al-Majed NS, McAlister FA, Bakal JA, et al. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Annals of internal medicine. 2011;154(6):401-412. doi:10.7326/0003-4819-154-6-201103150-00313

Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart (British Cardiac Society). 2015;101(22):1800-1806. doi:10.1136/heartjnl-2015-307634

Kutyifa V, Moss AJ, Solomon SD, et al. Reduced risk of life-threatening ventricular tachyarrhythmias with cardiac resynchronization therapy: relationship to left ventricular ejection fraction. European journal of heart failure. 2015;17(9):971-978. doi:10.1002/ejhf.311

Sapp JL, Parkash R, Wells GA, et al. Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial. Circulation Arrhythmia and electrophysiology. 2017;10(3). doi:10.1161/CIRCEP.116.004875

Gold MR, Linde C, Abraham WT, et al. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart rhythm. 2011;8(5):679-684. doi:10.1016/j.hrthm.2010.12.031

Barsheshet A, Wang PJ, Moss AJ, et al. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). Journal of the American College of Cardiology. 2011;57(24):2416-2423. doi:10.1016/j.jacc.2010.12.041

Leyva F, Zegard A, Umar F, et al. Long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2018;20(11):1804-1812. doi:10.1093/europace/eux357

Barra S, Boveda S, Providencia R, et al. Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate. Journal of the American College of Cardiology. 2017;69(13):1669-1678. doi:10.1016/j.jacc.2017.01.042

Kutyifa V, Geller L, Bogyi P, et al. Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience. European journal of heart failure. 2014;16(12):1323-1330. doi:10.1002/ejhf.185

Kober L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. The New England journal of medicine. 2016;375(13):1221-1230. doi:10.1056/NEJMoa1608029

Gras M, Bisson A, Bodin A, et al. Mortality and cardiac resynchronization therapy with or without defibrillation in primary prevention. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2020;22(8):1224-1233. doi:10.1093/europace/euaa096

Al-Sadawi M, Aslam F, Tao M, et al. Is CRT-D superior to CRT-P in patients with nonischemic cardiomyopathy? International Journal of Arrhythmia. 2023;24(1):3. doi:10.1186/s42444-023-00085-3

Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. The New England journal of medicine. 2009;361(14):1329-1338. doi:10.1056/NEJMoa0906431

Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. The New England journal of medicine. 2010;363(25):2385-2395. doi:10.1056/NEJMoa1009540

Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. Journal of the American College of Cardiology. 2008;52(23):1834-1843. doi:10.1016/j.jacc.2008.08.027

Hadwiger M, Dagres N, Haug J, et al. Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project. European heart journal. 2022;43(27):2591-2599. doi:10.1093/eurheartj/ehac053

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368

Normand C, Linde C, Bogale N, et al. Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?-findings from the ESC CRT Survey II. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2019;21(6):918-927. doi:10.1093/europace/euz002

Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. European heart journal. 2013;34(33):2592-2599. doi:10.1093/eurheartj/eht160

Barra S, Providencia R, Narayanan K, et al. Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. European heart journal. 2020;41(21):1976-1986. doi:10.1093/eurheartj/ehz773

Shen L, Jhund PS, Petrie MC, et al. Declining Risk of Sudden Death in Heart Failure. The New England journal of medicine. 2017;377(1):41-51. doi:10.1056/NEJMoa1609758

Medina-Ravell VA, Lankipalli RS, Yan GX, et al. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation. 2003;107(5):740-746. doi:10.1161/01.cir.0000048126.07819.37

Shukla G, Chaudhry GM, Orlov M, et al. Potential proarrhythmic effect of biventricular pacing: fact or myth? Heart rhythm. 2005;2(9):951-956. doi:10.1016/j.hrthm.2005.05.019

Leyva F, Zegard A, Acquaye E, et al. Outcomes of Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy. Journal of the American College of Cardiology. 2017;70(10):1216-1227. doi:10.1016/j.jacc.2017.07.712

Acosta J, Fernandez-Armenta J, Borras R, et al. Scar Characterization to Predict Life-Threatening Arrhythmic Events and Sudden Cardiac Death in Patients With Cardiac Resynchronization Therapy: The GAUDI-CRT Study. JACC Cardiovascular imaging. 2018;11(4):561-572. doi:10.1016/j.jcmg.2017.04.021

Linde C. CRT-P or CRT-D in heart failure patients: the RESET-CRT project-a prelude to the randomized controlled RESET-CRT study. European heart journal. 2022;43(27):2600-2602. doi:10.1093/eurheartj/ehac136